Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Key Points Question What is the efficacy and safety of HB0025, a novel programmed cell death 1 ligand 1/vascular endothelial growth factor bispecific antibody, combined with chemotherapy in patients with advanced non–small cell lung cancer? Findings In this phase 2 nonrandomized clinical trial of 169 patients, 20-mg/kg HB0025 plus chemotherapy yielded objective response rates of 57.1% in nonsquamous and 74.2% in squamous histologic types, with manageable toxic effects.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.